Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $103.4 million.

  • Rhythm Pharmaceuticals' Non-Current Debt changed N/A to $103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year change of. This contributed to the annual value of $108.3 million for FY2024, which is 200.3% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Non-Current Debt stood at $103.4 million for Q3 2025.
  • Rhythm Pharmaceuticals' 5-year Non-Current Debt high stood at $108.3 million for Q4 2024, and its period low was $103.4 million during Q3 2025.
  • Moreover, its 3-year median value for Non-Current Debt was $106.1 million (2023), whereas its average is $106.4 million.
  • Over the last 5 years, Rhythm Pharmaceuticals' Non-Current Debt had its largest YoY gain of 200.3% in 2024, and its largest YoY loss of 200.3% in 2024.
  • Quarter analysis of 3 years shows Rhythm Pharmaceuticals' Non-Current Debt stood at $106.1 million in 2023, then rose by 2.0% to $108.3 million in 2024, then dropped by 4.49% to $103.4 million in 2025.
  • Its last three reported values are $103.4 million in Q3 2025, $106.0 million for Q2 2025, and $107.9 million during Q1 2025.